Drug Name: Fruzaqla
Active Ingredient: fruquintinib
Indication: To treat refractory, metastatic colorectal cancer
Approval Date: 11/8/2023
Company: Takeda Pharmaceuticals America, Inc
More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf